Introduction and Aims {#sec1_1}
=====================

Gastric cancer is a major health problem, being the 5th most common cancer and the 3rd cause of cancer-related death \[[@B1]\]. Portugal is a country with a high/moderate incidence of gastric cancer \[[@B2]\], and the burden of digestive diseases increased in the past decade \[[@B3]\].

The increasing availability of upper digestive endoscopy, together with surveillance of patients with precancerous conditions \[[@B4]\], improves the detection rate of early neoplastic lesions that can be successfully treated with endoscopic resection, e.g., endoscopic submucosal dissection (ESD) or endoscopic mucosal resection.

Indeed, endoscopic resection is a minimally invasive treatment that has been shown to have a high efficacy in selected patients, with a better safety profile and a better quality of life than surgery \[[@B5],[@B6],[@B7]\]. Nevertheless, some disadvantages are also associated with endoscopic treatment. Namely, endoscopic resection is curative in 80-85% of the cases, meaning that 15-20% of the patients that are submitted to endoscopic resection will need to undergo gastrectomy with lymphadenectomy. Thus, the identification of risk factors for a non-curative resection is of paramount importance to improve patient selection. Additionally, patients with an early neoplastic lesion are at risk of developing metachronous lesions, and endoscopic surveillance is still required after endoscopic resection. The identification of risk factors for metachronous lesion development is also important to adapt surveillance to individual patients and to answer unsolved questions, such as when to stop surveillance. Furthermore, as 15-20% of the resections are considered non-curative, it is important to adapt patient management after an unsuccessful treatment in order to assess the clinical outcomes of available options (careful surveillance or surgical treatment).

The main aim of this study was to evaluate long-term outcomes of endoscopic resection, with special attention to management strategies after a non-curative resection. Secondary aims were to identify risk factors for a non-curative resection and for the development of metachronous lesions over time.

Patients and Methods {#sec1_2}
====================

Study Design, Setting, and Participants {#sec2_1}
---------------------------------------

This was a single-centre assessment of a cohort of consecutive patients with gastric superficial neoplasms submitted to ESD in IPO-Porto between October 2005 and July 2014 (retrospective assessment of prospectively collected data). Patients were included if there was an adequate follow-up (at least 18 months or until death) and excluded from analysis if resection was considered non-feasible (procedure interruption due to technical difficulties).

Patients were provided information about the benefits and risks of endoscopic resection, and when there was doubt about the best treatment method, patients were evaluated by a multidisciplinary team including gastroenterologists, oncologists, and surgeons; the patient\'s opinion was also part of the decision-making process.

Gastric ESD was performed by 2 operators (M.D.-R. and P.P.-N.) who had adequate training in this technique (animal models and supervised human training). Endoscopic evaluation and determination of margins was performed with chromoendoscopy with 0.5% indigo carmine, which was replaced by virtual chromoendoscopy with Narrow Band Imaging (Olympus®) after 2012. Small coagulation marks were made around the lesion (2-5 mm outside), and then submucosal injection was performed with saline, diluted epinephrine (1:100,000), and methylene blue. After elevation, 3-4 incisions were made with a needle knife (mainly HookKnife™; Olympus®) to get access to the submucosal layer, and an insulated-tip knife (mainly IT-Knife™; Olympus®) was used to perform circumferential dissection using the Endo Cut mode (Olympus electrosurgical unit, 80/60 W). Complete dissection was then performed in the Endo Cut mode, with additional submucosal injection whenever necessary. The procedures were performed mainly under general anaesthesia (with orotracheal intubation); deep sedation was restricted to a minority of procedures.

Patients received esomeprazol (80 mg), a proton pump inhibitor, as an intravenous bolus in the morning of the procedure and as a continuous intravenous infusion (8 mg/h for 48-72 h) after the procedure. Patients were given a liquid diet 24 h after the procedure and a soft diet after 48 h. In the absence of complications, patients were normally discharged 48-72 h after the procedure and instructed to take a proton pump inhibitor twice a day for 14 days and then a single dose until the next appointment, which was scheduled 4-8 weeks after discharge to discuss the histopathological results and to establish if additional treatment or endoscopic surveillance is needed.

When the resection met curative criteria, patients were included in an endoscopic surveillance program (with the first endoscopy being performed 3 months after ESD, the second 9 months after ESD, and yearly thereafter). Chromoendoscopy (conventional or electronic) was performed, and scar biopsies were collected if there was endoscopic suspicion of recurrence. Radiological surveillance in case of expanded criterion resections was performed at the discretion of the assistant physician. In patients with non-curative resection allocated for endoscopic surveillance (local-risk resections or high-risk resections in patients not fit for surgery or who refused surgery), scar biopsies were routinely performed. *Helicobacter pylori* eradication was also proposed to patients with curative resections.

Written informed consent was obtained from all patients. This study was conducted in accord with the ethical principles of the Declaration of Helsinki.

Definition of Variables {#sec2_2}
-----------------------

Data collection included clinical and demographic variables such as age, gender, ASA status (American Society of Anaesthesiologists\' classification of Physical Health), comorbidities and antithrombotic medication. Lesions were classified according to their size (endoscopic assessment and pathological measurements), morphology (according to the Paris classification \[[@B8]\]), presence of ulceration, and localization (upper, middle, or lower third of the stomach). Subsequently, lesions were classified into polypoid (0-Is, 0-Ip, or 0-Isp), non-polypoid, non-depressed (0-IIa, 0-IIa+b, or 0-IIb), and depressed (0-IIc component or 0-III). Synchronous lesions were divided into accessory lesions (less advanced lesions removed together with the main lesion) and synchronous lesions detected at the first follow-up. A lesion was considered metachronous when it was detected after the first endoscopic follow-up (i.e. at the second follow-up examination or later) in a different localization from the index lesion. Histological upgrade was considered when the histopathological evaluation of the resected specimen revealed a more advanced histology than the biopsies before resection.

Two pathologists with experience in gastrointestinal pathology performed the histopathological evaluation of the resected specimens, and the final diagnosis was made according to the Sydney-Vienna classification \[[@B9]\].

A complete resection (R0) was defined as an en bloc resection with free endoscopic and histological margins. Recurrence was defined as the appearance of a neoplastic lesion clearly at the site of the previous ESD. For risk stratification, the Japanese Classification of Gastric Cancer was used in routine clinical practice \[[@B10]\]. A curative resection was considered when the following criteria were met in a lesion completely resected, and when there was no lymphovascular or perineural invasion:

1.  dysplastic lesion of any size (standard criteria)

2.  intramucosal, ≤20 mm, well/moderately differentiated carcinoma without ulcerative findings (standard criteria)

3.  intramucosal, well/moderately differentiated carcinoma of any size without ulcerative findings (expanded criteria)

4.  intramucosal, well/moderately differentiated carcinoma with ulcerative findings, ≤30 mm (expanded criteria)

5.  well/moderately differentiated carcinoma, ≤30 mm, without ulcerative findings but with minute submucosal invasion (\<500 µm) (expanded criteria)

6.  poorly differentiated intramucosal carcinoma, ≤20 mm, without ulcerative findings (expanded criteria).

Additionally, a retrospective classification according to the recently published guidelines of the ESGE (European Society of Gastrointestinal Endoscopy) was also performed \[[@B11]\].

Patients with lesions not meeting criteria for curative resection were then evaluated in a multidisciplinary team that decided the approach according to the patients\' clinical condition, taking the patient\'s opinion and histopathological results into account.

Statistical Analysis {#sec2_3}
--------------------

Descriptive statistics were analyzed for each collected variable (means and SD for normally distributed continuous variables and medians and interquartile ranges when the distribution was not normal; frequencies and percentages for categorical variables). Continuous variables were compared between groups with independent samples *t* test or Mann-Whitney U test; for categorical variables, the χ^2^ test or Fisher exact test were used. Multivariate logistic regression models were constructed to identify significant predictors of non-curative resection and for metachronous lesion occurrence. Odds ratios (OR) were computed along with 95% confidence intervals (95% CI). Survival was analyzed using Kaplan-Meier curves and the log-rank test. Significance was defined as *p* ≤ 0.05.

In the analysis of short-term outcomes and risk factors for curative resection, a per lesion analysis was performed. A per patient analysis considering the moment from the first ESD was preferred when analyzing long-term outcomes (namely survival) and the incidence and risk factors for metachronous lesions.

Results {#sec1_3}
=======

During the study period, 164 patients (194 lesions) were submitted to ESD. ESD was not feasible in 6 additional patients that were scheduled for the procedure (5 due to inadequate elevation and 1 due to the occurrence of an uncontrolled intraoperative bleeding that needed surgery).

Short-Term Outcomes and Risk Factors for Non-Curative Resection {#sec2_4}
---------------------------------------------------------------

En bloc and complete resection was performed in 95.3 and 93.8%, respectively. Overall adverse events occurred in 13%; bleeding occurred in 8%, and muscular wall laceration or perforation in 3%. All adverse events were managed conservatively except in 1 patient with uncontrolled postoperative bleeding that required surgery.

Clinical, endoscopic, and pathological characteristics of the 194 ESD lesions are presented in Table [1](#T1){ref-type="table"} combined with the analysis of risk factors for non-curative resection. In univariate analysis, male sex, tumor size ≥20 mm, longer procedure time, and more advanced histology in biopsies before resection were associated with non-curative resection, although when adjusting for other factors (age, sex, tumor size, localization, and morphology) only carcinoma in biopsies was identified as an independent predictor of non-curative resection (adjusted OR 3.04, 95% CI 1.02-9.06). Tumor localization and morphology were not found to significantly influence the likelihood of a curative resection, although resection of polypoid lesions was non-curative in 23.5%. Piecemeal resection was associated with non-curative resection, although according to the ESGE guidelines a majority of these cases corresponded to local-risk resections due to indeterminate margins and were managed with endoscopic surveillance with additional treatments when necessary.

Histological upgrade (from low- to high-grade dysplasia or from high-grade dysplasia to carcinoma) occurred in 49.5% of the cases, with upgrade from dysplasia (low or high grade) to carcinoma being found in 31.4%.

Long-Term Outcomes {#sec2_5}
------------------

Table [2](#T2){ref-type="table"} summarizes risk stratification according to the ESGE guidelines. In 135 patients, the initial resection was considered curative (low-risk resection). There were 24 metachronous lesions in 21 patients (15.6%), with 19 being successfully treated with endoscopic resection. Two metachronous lesions were considered not suitable to endoscopic resection and were further treated with surgery, while 2 patients underwent non-curative ESD. Both patients refused surgery after discussion and no loco-regional or distant recurrence was found during follow-up (5 and 1.5 years). One patient with a metachronous dysplastic lesion refused any additional treatment.

Management and Clinical Outcomes after Non-Curative Resection {#sec2_6}
-------------------------------------------------------------

The most common reason for considering a resection as a local-risk resection was indeterminate or positive horizontal margins (Table [2](#T2){ref-type="table"}). Patients with high-risk resections frequently had more than 1 unfavourable prognostic criterion (mainly deep submucosal invasion and/or lymphovascular permeation).

In per-patient analysis, the first ESD was non-curative in 28 (10 local-risk resections and 18 high-risk resections according to the ESGE guidelines). Local-risk resections were managed with careful endoscopic surveillance (and radiologically where adequate, i.e. in cases with carcinoma in the histopathological specimen) in 9 patients; there was 1 metachronous lesion and 1 recurrence, both successfully treated with ESD. In the 18 high-risk resections, 12 underwent surgery while careful follow-up was decided in 6 patients. In the surveillance group, 2 patients had local recurrence that was successfully treated with endoscopic resection while 1 patient that refused surgery developed distant metastasis after 3 years and died of gastric cancer. There were 2 metachronous lesions in the same patients that had local recurrence, both treated with ESD. After gastrectomy, no residual disease was found in the gastrectomy specimen in 75%. There was nodal involvement in only 1 patient (with submucosal invasion ≥500 µm and lymphovascular invasion), while 2 had residual neoplasia in the gastric wall (corresponding to cases of piecemeal/R1 resection). Complications of gastrectomy occurred in 2 patients (16.7%). Of the patients submitted to gastrectomy, 1 died due to dehiscence and peritonitis, while 2 died 2 months after surgery due to comorbidity decompensation.

Metachronous Lesions - Incidence and Risk Factors {#sec2_7}
-------------------------------------------------

Globally, metachronous lesions occurred in 14.7%. When considering only patients allocated to endoscopic surveillance, the cumulative incidence was 18.4% (Fig. [1](#F1){ref-type="fig"}); 3 patients had ≥2 lesions. Metachronous lesions were detected at a median time of 24 months (interquartile range 9-50.25) and the incidence rate was 4.7/100 person-years. Older age at diagnosis (72.3 vs. 67.6 years) and male sex were significantly associated with a higher metachronous incidence in univariate analysis (*p* \< 0.05). However, multivariate analysis identified only age as a significant predictor for metachronous lesion occurrence (*p* = 0.042; OR~10\ years~ 1.68, 95% CI 1.03-2.74).

Survival {#sec2_8}
--------

In the entire cohort, overall survival was 94.5 and 89.5% at 1 and 3 years, respectively; disease-specific survival was 99.4%, with only 1 patient dying of gastric cancer. The median follow-up time was 40 months.

Survival was significantly higher in patients with curative resection (log-rank 4.538, *p* = 0.033; Fig. [2](#F2){ref-type="fig"}). In the non-curative resection group, patients submitted to surgery were significantly younger (mean age 66.7 ± 9.4 vs. 73.6 ± 7.5 in the follow-up group, *p* = 0.037) and less frequently classified as ASA III/IV (23.1 vs. 31.3%, *p* = 0.62). However, survival was not significantly different in the two groups (log-rank 0.009, *p* = 0.929; Fig. [2](#F2){ref-type="fig"}).

Comparing survival according to the ESGE criteria, survival in patients with high-risk resection was significantly worse than in patients with low-risk resection (log-rank 7.539, *p* = 0.006), while no significant differences were found in the survival of patients with low- and local-risk resection (log-rank 0.133, *p* = 0.715; Fig. [3](#F3){ref-type="fig"}).

Discussion and Conclusions {#sec1_4}
==========================

This study reports the long-term outcomes of gastric ESD in the largest cohort with the longest follow-up in a Western centre in Europe. We previously reported our initial experience with endoscopic mucosal resection and ESD in the treatment of gastric superficial neoplasms and found that ESD was associated with higher complete resection rates and lower recurrence rates, with similar complications \[[@B12]\]. The present study focused only on ESD in a larger cohort of patients with a longer follow-up. We evaluated the risk factors for non-curative resection, and the management and outcome after its occurrence. We found that carcinoma detected in biopsies before resection is an independent predictor of non-curative resection, and that surveillance may be an adequate option in older patients with non-curative resections. Additionally, we found that the incidence of metachronous lesions is significant and that older age is an independent predictor for its development.

Endoscopic resection with ESD is now considered a first-line treatment for early gastric neoplasms in European guidelines. The detection rate of these lesions is increasing, and technical advances facilitate the resection of lesions of increasing size and in difficult localizations.

However, endoscopic resection is non-curative in 80-85% of the cases \[[@B11],[@B12]\]. The long learning curve of ESD and the human and health care resources consumed by endoscopic resection are compelling factors to improve patient selection. Indeed, although it can be argued that endoscopic resection is the best staging for early lesions, it is important to select the patients with the best probability of a successful curative resection in order to make better use of health care resources and to manage patient expectations.

In this study, we identified male sex, tumor size ≥20 mm, a longer procedure time, and older age to be associated with treatment failure, although only carcinoma detected in biopsies before resection was an independent predictor for non-curative resection. The association of older age with non-curative resection is probably explained by selection bias, since the initial patients were typically those with a higher surgical risk and with more advanced lesions. The identification of carcinoma in histological sections before resection as an independent predictor of treatment failure is a novel and interesting finding. Indeed, although we know that histological upgrade frequently occurs when the entire tumor is evaluated in the resection specimen, biopsies reveal lesion features prior to treatment and can help in adequate selection, which improves the information transmitted to the patient, too. Lesion size ≥20 mm was also associated with non-curative resection, although it was not identified as an independent predictor. Nevertheless, data from other studies suggest that the likelihood of non-curative resection increases with increasing tumor size \[[@B13],[@B14]\]. Resection of polypoid lesions was frequently non-curative (23.5%), although the association was not statistically significant. These findings are in agreement with studies showing a higher probability of submucosal invasion in polypoid neoplastic lesions \[[@B8]\]. Although localization and morphology were not found to influence curability, data from other studies suggest that lesions located in the upper stomach and ulcerated lesions are also associated with non-curative resections \[[@B13],[@B14],[@B15]\].

The incidence of metachronous lesions was high, occurring in 18.4% of the patients during follow-up. The incidence rate of 5 lesions/100 patient-years means that, on average, one-fourth of the patients followed up for 5 years will have a metachronous lesion detected. One should expect that younger patients, which have a longer survival time (and thus more time to develop a metachronous lesion), could have a higher incidence of metachronous lesions. However, we found that patients with metachronous lesions are significantly older, and increasing age was identified as a significant predictor for the development of metachronous lesions, which may possibly be explained by the presumably higher prevalence of preneoplastic conditions. Unfortunately, information about preneoplastic conditions could not be retrieved from clinical records, and thus we could not evaluate the influence of preneoplastic conditions on metachronous lesion development. Our findings are in line with those from a recent large retrospective study where age was also associated with metachronous lesions \[[@B16]\]. Intestinal metaplasia and flat/depressed lesions were other factors that increase this risk. Surprisingly, our incidence rate was even higher than that reported in an Asian population (18.4/1,000 person-years) \[[@B17]\]. Our findings suggest that endoscopic surveillance is probably of benefit even 5 years after resection.

Another important issue is how to manage patients after non-curative resection. Even if granting curability is important in the majority of cases, patient age and comorbidities increase surgical risks, and surgery may be overtreatment in certain cases. Using the new risk stratification tool provided by the ESGE guidelines for the first time, we show favourable outcomes in patients with local-risk resections, with only 1 patient experiencing a recurrence that was successfully treated with further endoscopic resection. Survival was also not significantly different in patients with low- and local-risk resections. Additional findings suggest that surveillance may be a more adequate option in certain patients: (1) survival was similar in patients with non-curative resections independent of the treatment choice, although patients followed up were significantly older and more frequently ASA III/IV, and (2) 75% of the patients submitted to surgery did not have residual disease in the gastrectomy/lymphadenectomy specimen. However, an Asian study suggested that surgery is associated with a lower recurrence, especially in high-risk cases (incomplete resection in lesions exceeding curative criteria and lesions with lymphovascular invasion) \[[@B18]\]. Another study also suggested a survival benefit with surgery in cases of non-curative resection \[[@B19]\], although it is difficult to make definite conclusions because patients allocated to surveillance are generally older and have more comorbidities. We suggest that in high-risk resections the decision should be individualized, taking age, comorbidities, surgical risk, pathological features (with special attention to lymphovascular invasion), and patient preferences into account.

This study has some limitations. First, data on the influence of preneoplastic conditions and the *H. pylori* status on metachronous development was not available due to frequently missing data. Second, our cohort is smaller than those from Asian studies, and this study may be underpowered to detect the influence of risk factors such as morphology and localization.

Despite these limitations, this is the largest European cohort and the first European study that tried to identify risk factors for treatment failure and for metachronous lesion development, which is important to improve patient selection and adequate surveillance. Besides, the long follow-up indicates that ESD is associated with a high cancer-free survival and that surveillance may be appropriate in selected patients not strictly meeting criteria for curative therapy. Moreover, the high incidence of metachronous lesions alerts for the need of continuing endoscopic follow-up with special attention to older patients.

In conclusion, ESD is an effective and safe treatment for gastric superficial neoplasms and associated with a high cancer-free survival, although lifelong endoscopic surveillance may be necessary to detect metachronous lesions. Carcinoma detected in biopsies before resection is a significant predictor of treatment failure. Conservative management after non-curative resection is an option in selected patients, especially in local-risk resections.
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![Metachronous lesions occurred in 18.4% of the patients allocated for surveillance (incidence rate 4.7 lesions/100 person-years).](pjg-0024-0031-g01){#F1}

![Overall survival was similar in patients submitted to surgery and patients followed up (log-rank test 0.009, *p* = 0.929), although patients with non-curative resections had significantly lower survival (log-rank test 4.538, *p* = 0.033).](pjg-0024-0031-g02){#F2}

![Survival was not significantly different in patients with low- and local-risk resection; however, high-risk resection was significantly associated with a worse survival.](pjg-0024-0031-g03){#F3}

###### 

Risk factors for non-curative resection

                                                           Non-curative   Curative       *P* Value   OR (95% CI)          Adjusted OR (95% CI)
  -------------------------------------------------------- -------------- -------------- ----------- -------------------- ----------------------
  Age, years                                               70.5 ± 9.1     68.47 ± 10.7   0.329                            1.01 (0.97--1.05)
  Gender                                                                                                                  
   Males                                                   21 (20.2)      83 (79.8)      0.050       1.38 (1.05--1.83)    2.01 (0.84--4.81)
   Females                                                 9 (10)         81 (90)                    1                    1
  ASA status                                                                                                              
   ASA I/II                                                21 (13.5)      134 (86.5)                 1                    
   ASA III/IV                                              9 (23.1)       30 (76.9)      0.141       1.64 (0.87--3.09)    
  Median (SD) tumor size, mm                               26.1 (8.9)     19.9 (7.8)     0.001                            
  Tumor size                                                                                                              
   \<20 mm                                                 6 (8.1)        68 (91.9)                  1                    1
   ≥20 mm                                                  24 (20)        96 (80)        0.026       2.83 (1.09--7.30)    2.43 (0.91--6.54)
   Procedure time, min                                     104.7 ± 44.6   91.7 ± 58.7    0.031                            
  Localization                                                                                                            
   Upper                                                   5 (12.5)       35 (87.5)                  0.91 (0.30--2.71)    
   Middle                                                  11 (22)        39 (78)        0.338       1.79 (0.75--4.30)    
   Lower                                                   14 (13.6)      89 (86.4)                  1                    
  Morphology                                                                                                              
   Polypoid                                                4 (23.5)       13 (76.5)                  1.69 (0.47--6.1)     
   Non-polypoid, non-depressed                             12 (15.4)      66 (84.6)      0.613       1                    
   Depressed                                               14 (14.1)      85 (85.9)                  0.91 (0.39--2.1)     
  Biopsies before resection                                                                                               
   Low-grade dysplasia                                     6 (9.7)        56 (90.3)                  1                    1
   High-grade dysplasia[^a^](#T1F1){ref-type="table-fn"}   11 (12.8)      75 (87.2)      0.038       1.37 (0.48--3.92)    1.06 (0.36--3.14)
   Carcinoma[^a^](#T1F1){ref-type="table-fn"}              13 (28.9)      32 (71.1)                  3.79 (1.31--10.95)   3.04 (1.02--9.06)

Means ± SD or *n* (%) unless stated otherwise.

OR for carcinoma (vs. high-grade dysplasia) = 2.77 (1.12--6.83).

###### 

Risk stratification according to ESGE guidelines

  Risk stratification                                    *n* (%)      Criteria
  ------------------------------------------------------ ------------ ---------------------------------------------------
  Low-risk resection                                     164 (84.5)   126 standard criteria
                                                                      38 expanded criteria
  Local-risk resection                                   11 (5.7)     1 en bloc HM1/HMx dysplasia
                                                                      5 en bloc HM1/HMx carcinoma
                                                                      5 piecemeal (3 dysplasias, 2 carcinomas)
  High-risk resection[^a^](#T2F1){ref-type="table-fn"}   19 (9.8)     12 submucosal invasion ≥500 μm in a lesion ≥30 mm
                                                                      10 lymphovascular invasion
                                                                      4 poor differentiation and 2 mixed type ≥20 mm
                                                                      4 positive vertical margins

One criterion in 9; 2 criteria in 6; 3 criteria in 4. HM1/HMx, positive/indeterminate horizontal margins.
